Latest News

STAT Plus: Right to try ‘remains a bust,’ as many drug makers prefer FDA reviews

Despite the hubbub over the “right-to-try” law, a recent survey found that nearly half of drug makers indicated they would require regulators to review a decision to provide an experimental treatment to a person with a life-threatening disease.

Specifically, 13 of 29 drug companies indicated they want a relevant regulatory authority to review requests that are granted to such people. Of these, six specified they would ask the Food and Drug Administration to conduct a review and five stated they require a research ethics committee or institutional review board, according to a report from the Government Accountability Office.

Continue to STAT Plus to read the full story…

Source link




Related posts

Job Announcement: Technical Information Specialist (Bilingual – Spanish)

Newsemia

The association between loneliness and depressive symptoms among adults aged 50 years and older: a 12-year population-based cohort study

Newsemia

Bridging and Relevance

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy